CD8A and neoplasm: They consist of autologous CD4+ and CD8+ T cells that have been genetically modified to express a T-cell receptor (TCR) recognizing MAGE-A4 (afami-cel) or NY-ESO1 (lete-cel) bound to human leukocyte antigen A*02 (HLA-A*02) to induce anti-tumor responses in patients with SS and MLPS expressing those CTA.